{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:09:31Z","timestamp":1784624971646,"version":"3.55.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["Strategic Center of Biomedical Advanced Vaccine Re"],"award-info":[{"award-number":["Strategic Center of Biomedical Advanced Vaccine Re"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to determine the immunogenicity and the influence on disease activity of an adjuvanted recombinant varicella-zoster virus (VZV) subunit vaccine (RZV) in patients with rheumatoid arthritis (RA) treated with disease-modifying antirheumatic drugs (DMARDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective longitudinal study enrolled 53 patients with RA (aged \u226550 years) treated with DMARDs (conventional synthetic (cs)DMARDs 20, biological (b)DMARDs 23 and targeted synthetic (ts)DMARDs 10) and 10 control individuals. The participants received two intramuscular RZV 2 months apart. VZV-specific CD4<jats:sup>+<\/jats:sup> T cell responses (cell-mediated immunity; CMI) and IgG antibody responses (humoral immunity; HI) were assessed at 0 and 3 months after the first RZV administration using flow cytometry and enzyme immunoassay, respectively. Disease activity (Disease Activity Score 28-C reactive protein and Clinical Disease Activity Index), flares and adverse events were monitored for 6 months after the first vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>VZV-specific CMI and HI significantly increased in the three DMARDs-treated patients with RA after RZV administration compared with the corresponding prevaccination values (p&lt;0.001\u20130.014), and the magnitudes and fold-increases of those responses were not significantly different among the three DMARDs-treated patients with RA. Furthermore, the vaccine response rates of CMI and HI were not significantly different between csDMARDs-treated patients and b-DMARDs or ts-DMARDs-treated patients. Meanwhile, no significant increases in disease activity indices or adverse events were observed in these patients during the 6-month follow-up period after the first vaccination. RZV-induced RA flares occurred in two patients (3.8%) but were mild and controllable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>RZV is robustly immunogenic and has a clinically acceptable safety profile in elderly patients with RA receiving DMARDs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003902","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T01:54:27Z","timestamp":1708566867000},"page":"e003902","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-6953","authenticated-orcid":false,"given":"Shotaro","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-3518","authenticated-orcid":false,"given":"Taro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-937X","authenticated-orcid":false,"given":"Yoshihisa","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0144-9606","authenticated-orcid":false,"given":"Manami","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seikeikai Chiba Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-458X","authenticated-orcid":false,"given":"Fumiyoshi","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seikeikai Chiba Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-336X","authenticated-orcid":false,"given":"Tomoaki","family":"Ida","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-7624","authenticated-orcid":false,"given":"Junya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6268-3890","authenticated-orcid":false,"given":"Yosuke","family":"Toda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-8382","authenticated-orcid":false,"given":"Kazusa","family":"Miyachi","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8771-481X","authenticated-orcid":false,"given":"Arifumi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-2685","authenticated-orcid":false,"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"},{"name":"Department of Rheumatology, Dokkyo Medical University, Mibu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-9381","authenticated-orcid":false,"given":"Hiroshi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan"},{"name":"Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2025090313444516000_10.1.e003902.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1310369"},{"key":"2025090313444516000_10.1.e003902.2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes Zoster in rheumatoid arthritis: population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313444516000_10.1.e003902.3","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes Zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313444516000_10.1.e003902.4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes Zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313444516000_10.1.e003902.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220651"},{"key":"2025090313444516000_10.1.e003902.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209131"},{"key":"2025090313444516000_10.1.e003902.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"2025090313444516000_10.1.e003902.8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"2025090313444516000_10.1.e003902.9","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and Immunogenicity of live Zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090313444516000_10.1.e003902.10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7326\/M20-6928","article-title":"The safety and immunologic effectiveness of the live Varicella-Zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial","volume":"174","author":"Curtis","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025090313444516000_10.1.e003902.11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis638"},{"key":"2025090313444516000_10.1.e003902.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"2025090313444516000_10.1.e003902.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"2025090313444516000_10.1.e003902.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090313444516000_10.1.e003902.15","doi-asserted-by":"publisher","DOI":"10.1086\/605611"},{"key":"2025090313444516000_10.1.e003902.16","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00095-12"},{"key":"2025090313444516000_10.1.e003902.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm1293"},{"key":"2025090313444516000_10.1.e003902.18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy095"},{"key":"2025090313444516000_10.1.e003902.19","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313444516000_10.1.e003902.20","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes Zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090313444516000_10.1.e003902.21","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_31"},{"key":"2025090313444516000_10.1.e003902.22","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.vaccine.2011.04.019","article-title":"Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection","volume":"29","author":"Oxman","year":"2011","journal-title":"Vaccine"},{"key":"2025090313444516000_10.1.e003902.23","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes Zoster and the severity of skin symptoms and Zoster-associated pain: the SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"2025090313444516000_10.1.e003902.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121484"},{"key":"2025090313444516000_10.1.e003902.25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1265715"},{"key":"2025090313444516000_10.1.e003902.26","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309345724"},{"key":"2025090313444516000_10.1.e003902.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2019.02.009"},{"key":"2025090313444516000_10.1.e003902.28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit365"},{"key":"2025090313444516000_10.1.e003902.29","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant Zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313444516000_10.1.e003902.30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the Zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center\u2019s experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:44:54Z","timestamp":1756932294000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,21]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/rmdopen-2023-003902"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003902","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}